Abstract
The traditional perspective of applying neurotrophins in the context of Alzheimers disease is based on the premise that neurotrophins are capable of upregulating cholinergic function and of rendering neurons less vulnerable to certain processes causing degeneration. Factors limiting the therapeutic application of neurotrophin proteins include their poor pharmacological properties and their pleiotropic effects mediated by interaction with Trk, p75NTR and sortilin receptors. Recent studies suggesting and that pro-forms of neurotrophins accumulating in Alzheimers and other pathological states cause cell death, that p75NTR modulates amyloid beta- and injury-induced neurodegeneration and that small molecules can be created that bind specifically to individual neurotrophin receptors point to novel strategies by which neurotrophin receptors might be targeted in Alzheimers and other neuropathological states.
Keywords: neurotrophin, trk tyrosine kinase receptors, protein kinase c (pkc), neuropathies, schwann cell hypertrophy, expression, ngf loop, antisense, neuroprotection
Current Alzheimer Research
Title: Neurotrophin Receptor-Based Strategies for Alzheimers Disease
Volume: 2 Issue: 2
Author(s): Frank M. Longo and Stephen M. Massa
Affiliation:
Keywords: neurotrophin, trk tyrosine kinase receptors, protein kinase c (pkc), neuropathies, schwann cell hypertrophy, expression, ngf loop, antisense, neuroprotection
Abstract: The traditional perspective of applying neurotrophins in the context of Alzheimers disease is based on the premise that neurotrophins are capable of upregulating cholinergic function and of rendering neurons less vulnerable to certain processes causing degeneration. Factors limiting the therapeutic application of neurotrophin proteins include their poor pharmacological properties and their pleiotropic effects mediated by interaction with Trk, p75NTR and sortilin receptors. Recent studies suggesting and that pro-forms of neurotrophins accumulating in Alzheimers and other pathological states cause cell death, that p75NTR modulates amyloid beta- and injury-induced neurodegeneration and that small molecules can be created that bind specifically to individual neurotrophin receptors point to novel strategies by which neurotrophin receptors might be targeted in Alzheimers and other neuropathological states.
Export Options
About this article
Cite this article as:
Longo M. Frank and Massa M. Stephen, Neurotrophin Receptor-Based Strategies for Alzheimers Disease, Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585819
DOI https://dx.doi.org/10.2174/1567205053585819 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors
Current Pharmaceutical Design Targeting PPAR Isoforms Following CNS Injury
Current Drug Targets The Association of Neuronal Stress with Activating Transcription Factor 3 in Dorsal Root Ganglion of in vivo and in vitro Models of Bortezomib- Induced Neuropathy
Current Cancer Drug Targets Neuroprotection by Estrogen and Progesterone in Traumatic Brain Injury and Spinal Cord Injury
Current Neuropharmacology Dimethyl Sulfoxide as an Excitatory Modulator and its Possible Role in Cancer Pain Management
Inflammation & Allergy - Drug Targets (Discontinued) Ion Selective Electrodes for Potentiometric Determination of Tizanidine in Its Pharmaceutical Dosage Form
Current Pharmaceutical Analysis Extracellular Vesicles as Innovative Tools for Assessing Adverse Effects of Immunosuppressant Drugs
Current Medicinal Chemistry Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke
Current Pharmaceutical Design Use of Hemoglobin for Delivering Exogenous Carbon Monoxide in Medicinal Applications
Current Medicinal Chemistry Pharmacological Modulation of the State of Awareness in Patients with Disorders of Consciousness: An Overview
Current Pharmaceutical Design Astrocytes Exert and Control Immune Responses in the Brain
Current Immunology Reviews (Discontinued) Editorial [Hot Topic: An Update on Neurotrophins (Guest Editor: Celia Duarte Cruz)]
Current Neuropharmacology Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Matter of Life and Death: the Pharmacological Approaches Targeting Apoptosis in Brain Diseases
Current Pharmaceutical Design Sources of β-Cells for Cell Therapy in Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Endocannabinoid System and Multiple Sclerosis
Current Pharmaceutical Design Mesenchymal Stem Cells Targeting of Systemic Disorders in Age-related Macular Degeneration
Current Tissue Engineering (Discontinued) Pharmacological Benefits of Active Components of Natural Products Against Traumatic Brain Injury - A Review
Current Pharmacogenomics and Personalized Medicine The Therapeutic Potential of Neural Stem Cells in Traumatic Brain Injuries
Current Signal Transduction Therapy Therapeutic Potential of Cannabinoids in Trigeminal Neuralgia
Current Drug Targets - CNS & Neurological Disorders